PURPOSE: To evaluate the safety and efficacy of MR-guided radiofrequency ablation (RFA) of hepatic neoplasms. MATERIAL AND METHODS: 16 hepatic neoplasms (1.3-3.0 cm in diameter) in 11 patients were treated by 22 percutaneous RFA sessions during a prospective study. 16 G, MR-compatible cooled-tip electrodes with active lengths of 2 cm and 3 cm, respectively, were placed under MR-guidance in an open 0.2 Tesla MR system (Magnetom Open, Siemens, Erlangen) using fast T1-weighted sequences. Pretreatment studies, evaluation of tumor necrosis (one week after last RFA), and further follow-up studies every 3 months were performed using 1.5 Tesla MR systems. RESULTS: The mean procedure time was 2.8 (1.5-3.3) h. Complications related to percutaneous treatment were not encountered. 14 of 16 neoplasms (87%) showed no CM enhancement during MRI after the last RFA and were judged to be completely necrotic. In 11 tumors one treatment session was necessary, in 4 tumors two and in one tumor three. Follow-up studies revealed persistent complete necrosis in 13 of 14 (93%) tumors during a period of 3-18 (median: 11.8) months. In 5 patients new intrahepatic tumors developed that were not suitable for further RFA treatment because of their number, size and location. CONCLUSION: MR-guided RFA using single cooled tip electrodes is safe and technically effective for treatment of hepatic neoplasms up to 3 cm in size, however further improvements are necessary.
PURPOSE: To evaluate the safety and efficacy of MR-guided radiofrequency ablation (RFA) of hepatic neoplasms. MATERIAL AND METHODS: 16 hepatic neoplasms (1.3-3.0 cm in diameter) in 11 patients were treated by 22 percutaneous RFA sessions during a prospective study. 16 G, MR-compatible cooled-tip electrodes with active lengths of 2 cm and 3 cm, respectively, were placed under MR-guidance in an open 0.2 Tesla MR system (Magnetom Open, Siemens, Erlangen) using fast T1-weighted sequences. Pretreatment studies, evaluation of tumor necrosis (one week after last RFA), and further follow-up studies every 3 months were performed using 1.5 Tesla MR systems. RESULTS: The mean procedure time was 2.8 (1.5-3.3) h. Complications related to percutaneous treatment were not encountered. 14 of 16 neoplasms (87%) showed no CM enhancement during MRI after the last RFA and were judged to be completely necrotic. In 11 tumors one treatment session was necessary, in 4 tumors two and in one tumor three. Follow-up studies revealed persistent complete necrosis in 13 of 14 (93%) tumors during a period of 3-18 (median: 11.8) months. In 5 patients new intrahepatic tumors developed that were not suitable for further RFA treatment because of their number, size and location. CONCLUSION: MR-guided RFA using single cooled tip electrodes is safe and technically effective for treatment of hepatic neoplasms up to 3 cm in size, however further improvements are necessary.
Authors: Andreas Boss; Petros Martirosian; Christina Schraml; Stephan Clasen; Michael Fenchel; Artistotelis Anastasiadis; Claus D Claussen; Philippe L Pereira; Fritz Schick Journal: Eur Radiol Date: 2006-01-27 Impact factor: 5.315
Authors: Christina Schraml; Hansjörg Graf; Andreas Boss; Stephan Clasen; Martin Leibfritz; Philippe L Pereira; Claus D Claussen; Fritz Schick Journal: MAGMA Date: 2005-12-13 Impact factor: 2.310
Authors: Jens Ricke; Markus Thormann; Matthias Ludewig; Kerstin Jungnickel; Oliver Grosser; Christian Wybranski; Nils Peters; Peter Hass; Jürgen Bunke; Frank Fischbach Journal: Eur Radiol Date: 2010-03-20 Impact factor: 5.315
Authors: Alexis D Kelekis; Sylvain Terraz; André Roggan; François Terrier; Pietro Majno; Gilles Mentha; Arnaud Roth; Christoph D Becker Journal: Eur Radiol Date: 2003-03-26 Impact factor: 5.315
Authors: Rebecca Kokes; Kevin Lister; Rao Gullapalli; Bao Zhang; Alan MacMillan; Howard Richard; Jaydev P Desai Journal: Med Image Anal Date: 2009-02-20 Impact factor: 8.545